EURESTOP network aims to tackle antibiotic resistance crisis

There is compelling evidence that bacteria, parasites, viruses, and fungi are developing resistance to antimicrobials. As a result, infections in humans, animals, and plants are becoming increasingly difficult, and in some cases impossible, to treat.

Formosa and Tabuk sign deal for ophthalmic suspension

The formulation offers a convenient dosing regimen, requiring administration only twice daily for 14 days. Credit: megaflopp / Shutterstock.com. Formosa Pharmaceuticals has announced an exclusive

May 10, 2024

Enara Bio secures $32.5m for ‘Dark Antigen’ cancer therapies – Pharmaceutical Technology

The dark matter of the genome is the majority of the human genome, making up around 98% of it. Image credit: Shutterstock/ Tartila. Enara Bio

October 3, 2024

Scientists delve deeper into how vaccines work against leishmaniasis

Scientists have established the effectiveness of vaccines they developed to prevent the disfiguring skin disease leishmaniasis in animal studies, and Phase 1 human trial planning

September 1, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.